Oncothyreon Inc. (ONTY) is a $300 million market cap company that trades an average of 2.24 million shares per day. Analysts are expecting an improvement of $0.08 in earnings per share compared to last quarter's results of $-0.23. The company was founded in 1985 and is headquartered in Seattle, Washington.
- Time Released: After close
- Industry: Biotechnology & Drugs
- Recent Price: $7.20
- 52 Week High: $11.59
- 52 Week Low: $2.99
- Book Value: $0.40
A beat of $-0.15 per share will top the estimated mean earnings. Analyst estimates range between $-0.17 and $-0.14 per share.
The company has falling revenue year-over-year of $0.02 million for 2010 vs. $2.08 million for 2009. The bottom line has rising earnings year-over-year of $-15.62 million for 2010 vs. $-17.22 million for 2009. The company's earnings before income and taxes are falling, as well. EBIT year-over-year is $-19.48 million for 2010 vs. $-10.86 million for 2009.
Do you think Oncothyreon will miss or beat, and why? Use the comments below to share your opinion.
Gross reported revenue compared to the mean estimate (rounded).
|Fiscal Quarter Ending Month-Year||Revenue Estimates||Actual||$ Difference||Difference %|
|Mar-11||$ 1.27M||$ 0.14M||$ -1.13M||-88.98%|
|Dec-10||$ 0.01M||$ 0.00M||$ -0.01M||NA%|
|Sep-10||$ 0.05M||$ 0.00M||$ -0.05M||NA%|
|Jun-10||$ 0.01M||$ 0.00M||$ -0.01M||NA%|
|Dec-09||$ -0.12M||$ -0.10M||$ 0.02M||NA%|
M = millions, B = billions
Reported earnings per share compared to the mean estimate. Differences are rounded.
|Fiscal Quarter Ending Month-Year||Estimate||Actual||Difference||Difference %|
(Some onetime items are often excluded in reported EPS.)
I use a proprietary blend of technical analysis, financial crowd behavior, and fundamentals in my short-term trades, and while not totally the same in longer swing trades to investments, the concepts used are similar. You may want to use this article as a starting point of your own research with your financial planner. I use Seeking Alpha, Edgar Online, Google Finance, MSN Money, CNBC, Zacks and Yahoo Finance for most of my data. I use the "confirmed" symbols from earnings.com that I believe to be of the most interest. I also often include some that are not "confirmed" but are "Proposed" for the same day. The numbers are only as good as the sources. Many of the ADRs that are relatively new provide a special challenge that can be very time consuming to figure out the "best" number. Chinese ADRs that are new seem to be especially prone to conflicts with Reuters, EDGAR Online, and other sources. Not everyone puts companies into the same sector. I use Reuters as my primary guide to keep it consistent.